Abstract
Eighteen patients with leiomyomata uteri were randomized to receive either leuprolide acetate depot (n = 9) 3.75 mg intramuscularly (IM) or placebo (n = 9) IM every 4 weeks for four injections. Leuprolide acetate treated patients demonstrated a reduction in mean uterine volume of 34% and a decrease in serum estradiol (E2) concentrations from 120 +/- 21 pg/mL (mean +/- standard error) to 16 +/- 9 pg/mL. Leuprolide acetate treated patients also demonstrated significant decreases in serum growth hormone (GH) (3.0 +/- 0.4 ng/mL versus 1.4 +/- 0.4 ng/mL) and insulin-like growth factor-I (IGF-I) concentrations (3.3 +/- 0.4 U/mL versus 1.3 +/- 0.2 U/mL) over the 12 week treatment period. Serum IGF-II levels did not change. Mean uterine volume and serum E2, GH, IGF-I, and IGF-II concentrations did not change in placebo-treated patients. These data suggest that hypoestrogenism is associated with decreases in circulating GH and IGF-I.
Publication types
-
Clinical Trial
-
Comparative Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Estradiol / blood
-
Fasting
-
Female
-
Gonadotropin-Releasing Hormone / analogs & derivatives*
-
Gonadotropin-Releasing Hormone / therapeutic use
-
Growth Hormone / blood*
-
Hormones / therapeutic use
-
Humans
-
Insulin-Like Growth Factor I / metabolism*
-
Insulin-Like Growth Factor II / metabolism*
-
Leiomyoma / blood*
-
Leiomyoma / drug therapy
-
Leiomyoma / pathology
-
Leuprolide
-
Placebos
-
Somatomedins / metabolism*
-
Uterine Neoplasms / blood*
-
Uterine Neoplasms / drug therapy
-
Uterine Neoplasms / pathology
-
Uterus / drug effects
-
Uterus / pathology
Substances
-
Antineoplastic Agents
-
Hormones
-
Placebos
-
Somatomedins
-
Gonadotropin-Releasing Hormone
-
Estradiol
-
Insulin-Like Growth Factor I
-
Insulin-Like Growth Factor II
-
Growth Hormone
-
Leuprolide